scholarly journals Lymphoid blast crisis after prolonged treatment‐free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de‐escalation during the COVID‐19 pandemic

eJHaem ◽  
2021 ◽  
Author(s):  
Daniele Avenoso ◽  
Dragana Milojkovic ◽  
James Clark ◽  
Christopher Pocock ◽  
Victoria Potter ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukaemia ◽  
Kinase Inhibitor ◽  
Blast Crisis ◽  
Prolonged Treatment ◽  
Treatment Free Remission

scholarly journals Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice

2019 ◽  
Vol 14 (6) ◽  
pp. 507-514 ◽  
Author(s):  
Richard E. Clark
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukaemia ◽  
Kinase Inhibitor ◽  
Molecular Response ◽  
Therapy Discontinuation ◽  
Tyrosine Kinase Inhibitor Therapy ◽  
Treatment Free Remission ◽  
Inhibitor Treatment

Abstract Purpose In chronic myeloid leukaemia, tyrosine kinase inhibitor treatment is traditionally given continuously for life. However, these drugs produce excellent responses for many patients, and this is accompanied by survival that is close to normal. This has prompted studies of whether it is possible to stop treatment, thus achieving a treatment-free remission (TFR). Recent Findings Most TFR studies have focussed on abrupt cessation in patients with long-standing deep remissions, but recent data suggest that more gradual treatment de-escalation may improve TFR success, and that it may be possible to extend TFR attempts to patients who are in stable major molecular response but not necessarily MR4. Summary Further data are badly needed on TFR for patients whose remission is less than stable MR4 and on the importance of prior interferon-alpha treatment. Funding TFR trials in a disease with such an excellent outlook is an increasing challenge.

scholarly journals Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium

2019 ◽  
Vol 142 (4) ◽  
pp. 197-207 ◽  
Author(s):  
Timothy Devos ◽  
Gregor Verhoef ◽  
Eva Steel ◽  
Dominiek Mazure ◽  
Philippe Lewalle ◽  
...  
Keyword(s):  
Side Effects ◽  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukaemia ◽  
Kinase Inhibitor ◽  
Chronic Phase ◽  
Molecular Response ◽  
Treatment Free Remission ◽  
Tki Treatment

Objectives: To assess interruptions/discontinuations of tyrosine kinase inhibitor (TKI) treatment in Belgian patients with chronic myeloid leukaemia (CML). Methods: This retrospective study included patients with TKI interruptions/discontinuations of ≥4 continuous weeks (no clinical trial context) between May 2013 and May 2016. Data collection took place between October 2016 and February 2017. Results: All 60 participants (69 interruptions/discontinuations) had chronic-phase CML and 75% had at least a major molecular response (≥MMR) at interruption/discontinuation. Most interruptions/discontinuations occurred while on imatinib (36/69; 49%) and dasatinib (20/69; 29%). Most interruptions/discontinuations occurred due to side effects/intolerance (46/69; 67%); other reasons included a wish to conceive (6/69; 9%) and attempts to achieve treatment-free remission (TFR) (6/69; 9%). Interruptions due to side effects occurred later for imatinib- or dasatinib-treated patients than for those on nilotinib or ponatinib. Treatment was re-initiated in 62% (43/69) of cases. Most interruptions caused by side effects/intolerance were followed by treatment changes. All 4 patients with ≥MR 4.5 at interruption/discontinuation and ≥11-month follow-up who had not restarted treatment maintained the response. Conclusion: Although TKIs are used for long-term CML treatment, physicians sometimes recommend interruptions/discontinuations. In this study, interruptions/discontinuations were mainly caused by side effects or intolerance, rather than TFR attempts.

Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia

2016 ◽  
Vol 91 (11) ◽  
pp. E480-E481 ◽  
Author(s):  
Simone Claudiani ◽  
Jane F. Apperley ◽  
Simona Deplano ◽  
Jamshid Khorashad ◽  
Letizia Foroni ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukaemia ◽  
Cognitive Dysfunction ◽  
Kinase Inhibitor ◽  
Inhibitor Therapy ◽  
Tyrosine Kinase Inhibitor Therapy

scholarly journals Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

2015 ◽  
Vol 169 (5) ◽  
pp. 683-688 ◽  
Author(s):  
Niklas Gunnarsson ◽  
Leif Stenke ◽  
Martin Höglund ◽  
Fredrik Sandin ◽  
Magnus Björkholm ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukaemia ◽  
Kinase Inhibitor ◽  
Second Malignancies

scholarly journals GRP-011 Adherence to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

2013 ◽  
Vol 20 (Suppl 1) ◽  
pp. A4.3-A5
Author(s):  
V González Rosa ◽  
MM Viña Romero ◽  
F Gutiérrez Nicolás ◽  
R Gavira Moreno ◽  
MT Moreno Carvajal ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukaemia ◽  
Kinase Inhibitor ◽  
Inhibitor Therapy ◽  
Tyrosine Kinase Inhibitor Therapy

CP-214 Adherence to tyrosine kinase inhibitor treatments in chronic myeloid leukaemia: A pilot study

2016 ◽  
Vol 23 (Suppl 1) ◽  
pp. A94.2-A95
Author(s):  
A Andújar-Mateos ◽  
AM Sánchez García ◽  
A Martínez Valero ◽  
R Antón Torres ◽  
FJ Rodríguez-Lucena ◽  
...  
Keyword(s):  
Pilot Study ◽  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukaemia ◽  
Kinase Inhibitor

Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register

2016 ◽  
Vol 98 (1) ◽  
pp. 57-66 ◽  
Author(s):  
Stina Söderlund ◽  
Torsten Dahlén ◽  
Fredrik Sandin ◽  
Ulla Olsson-Strömberg ◽  
Maria Creignou ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukaemia ◽  
Kinase Inhibitor ◽  
Advanced Phase
Sign in / Sign up

Export Citation Format

Share Document